1-(2-氯乙基)-3-(萘-2-基)脲 | 13908-57-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(2-氯乙基)-3-(萘-2-基)脲
• 英文名称: 1-(2-chloroethyl)-3-(2-naphthyl)-urea
• 英文别名: 1-(2-chloro-ethyl)-3-naphthalen-2-yl-urea；1-(2-chloroethyl)-3-naphthalen-2-ylurea；Urea, 1-(2-chloroethyl)-3-(2-naphthyl)-
• CAS: 13908-57-1
• 化学式: C₁₃H₁₃ClN₂O
• 分子量: 248.712
• InChiKey: BMPINTUZIXWLFQ-UHFFFAOYSA-N

物化性质

• 熔点：
  185-187 °C
• 沸点：
  399.1±34.0 °C(Predicted)
• 密度：
  1.286±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-氯乙基)-3-(萘-2-基)脲 在 sodium hydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(naphthalen-2-yl)imidazolidin-2-one
  参考文献：
  名称：

  Inhibitors of CYP 17

  摘要：

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐， 其中R 53 ，R 54 ，p，q和n如本文所述定义。本发明的化合物被发现作为17α-羟化酶/C 17,20 -裂解酶抑制剂是有用的。

  公开号：

  US20100331326A1
• 作为产物：
  描述：

  氯乙基异氰酸酯 、 2-萘胺 以40%的产率得到1-(2-氯乙基)-3-(萘-2-基)脲
  参考文献：
  名称：

  抗有丝分裂抗肿瘤剂：N-芳基-N'-（2-氯乙基）脲作为新型选择性烷基化剂的合成，构效关系和生物学表征。

  摘要：

  合成了一系列的N-芳基-N'-（2-氯乙基）脲（CEU）及其衍生物，并评估了其对多种肿瘤细胞系的抗增殖活性。系统结构-活性关系（SAR）研究表明：（i）苯环或芴基/茚满基4位上的支链烷基链或卤素，（ii）外环脲官能团，和（iii） ）需要N'-2-氯乙基部分以确保明显的细胞毒性。诸如免疫荧光显微镜等生物学实验证实，这些有前途的化合物通过β-微管蛋白的选择性烷基化诱导微管解聚，从而改变了细胞骨架。随后的评估表明，有效的CEU是弱烷基化剂，是非DNA破坏剂，并且不与谷胱甘肽或谷胱甘肽还原酶的硫醇功能相互作用。因此，CEU是新型抗有丝分裂剂的一部分。最后，在评估的一系列CEU中，选择了化合物12、15、16和27用于进一步的体内试验。

  DOI：

  10.1021/jm0010264

文献信息

• [EN] 1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17<br/>[FR] DÉRIVÉS D'IMIDAZOLIDIN-2-ONE 1,3-DISUBSTITUÉS EN TANT QU'INHIBITEURS DE CYP 17
  申请人：NOVARTIS AG

  公开号：WO2010149755A1

  公开（公告）日：2010-12-29

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

  本发明提供了式(I)和(II)的化合物，或其药用可接受的盐，其中R53、R54、p、q和n按本说明书中定义。本发明的化合物被发现作为17α-羟化酶/C17,20-裂合酶抑制剂是有用的。
• INHIBITORS OF CYP 17
  申请人：BOCK Mark Gary

  公开号：US20140228394A1

  公开（公告）日：2014-08-14

  The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R 53 , R 54 , p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C 17,20 -lyase inhibitors.

  本发明提供了公式(I)和(II)化合物，或其药学上可接受的盐，其中R53、R54、p、q和n的定义如本文所述。本发明的化合物已被发现可以作为17α-羟化酶/C17,20-裂解酶抑制剂使用。
• The Synthesis of Potential Anticancer Agents. XXXVI. N-Nitrosoureas.¹ II. Haloalkyl Derivatives
  作者：Thomas P. Johnston、George S. McCaleb、Pamela S. Opliger、John A. Montgomery

  DOI：10.1021/jm00324a026

  日期：1966.11
• Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation
  作者：Jessica S. Fortin、Marie-France Côté、Jacques Lacroix、Alexandre Patenaude、Éric Petitclerc、René C.-Gaudreault

  DOI：10.1016/j.bmcl.2008.05.028

  日期：2008.6

  1-(2-Chloroethyl)-3-(4-cyclohexylphenyl) urea (cHCEU) has been shown to abrogate the presence of thioredoxin-1 into the nucleus through its selective covalent alkylation. In the present letter we have evaluated the structure-activity relationships of the substituents at positions 3 and 4 of the phenyl ring of cHCEU derivatives on cell cycle progression and thioredoxin-1 nuclear translocation. Active CEU derivatives exhibited GI(50) ranging from 1.9 to 49 mu M on breast carcinoma MCF-7, skin melanoma M21, and colon carcinoma HT-29 cells. On one hand, compounds 1, 2, 9c, 10c, 13, and 14 arrested the cell cycle in G(2)/M phase while CEUs 3, 4, 5c, 6c, 11c, and 12c blocked the cell division in G(0)/G(1) phase. On the other hand, CEUs 2-4, 5c, 7c, 8c, 11c, and 12c abrogated the translocation of thioredoxin-1 while the other CEU derivatives were inactive in that respect. Our results suggest that CEU substituted on the phenyl ring at position 3 or 4 by lower cycloalkyl or cycloalkoxy groups arrest cell progression in G(0)/G(1) phase through mechanism of action different from their antimicrotubule counterparts, presumably via thioredoxin-1 alkylation and modulation of its activity. The mechanism of action of these new molecules is still undetermined. However, the significant accumulation of cells in G(0)/G(1) phase suggests that these molecules may act similarly to known chemopreventive agents against cancers. In addition, the inhibition of Trx-1 nuclear localization also suggests the abrogation of an important chemoresistance mechanism towards a variety of chemotherapeutic agents. (C) 2008 Elsevier Ltd. All rights reserved.
• Aromatic 2-chloroethyl urea derivatives and bioisosteres. Part 2: Cytocidal activity and effects on the nuclear translocation of thioredoxin-1, and the cell cycle progression
  作者：Jessica S. Fortin、Marie-France Côté、Jacques Lacroix、Éric Petitclerc、René C.-Gaudreault

  DOI：10.1016/j.bmc.2008.06.006

  日期：2008.8

  Recently, a subset of N-phenyl-N'-(2-chloroethyl) ureas (CEU) was found abrogating the nuclear translocation of thioredoxin-1 and arresting the cell cycle in G(0)/G(1) phase. Several derivatives were prepared to assess their effect on cell cycle progression and on the intracellular location of Trx-1. Compounds 1-20, 21-40, and 41-60 exhibited GI(50) between 1 and 80 mu M. Immunocytochemistry analysis showed compounds 4, 6, 8, 10, 11, 23, 24, 26-31, 34, 37, 41, 44, 46-51, 53, 56, and 57 inhibiting the nuclear translocation of Trx-1. Our results suggest that increasing the electrophilic character of these molecules might enhance the antiproliferative activity at the expense of the selectivity toward thioredoxin-1 and the G(0)/G(1) phase arrest. (C) 2008 Elsevier Ltd. All rights reserved.

表征谱图